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LMP1 signaling pathway activates IRF4 in latent EBV infection 
and a positive circuit between PI3K and Src is required
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Abstract
Interferon (IFN) regulatory factors (IRFs) have crucial roles in immune regulation and 
oncogenesis. We have recently shown that IRF4 is activated through c-Src-mediated tyrosine 
phosphorylation in virus-transformed cells. However, the intracellular signaling pathway 
triggering Src activation of IRF4 remains unknown. In this study, we provide evidence that 
Epstein–Barr virus (EBV) latent membrane protein 1 (LMP1) promotes IRF4 phosphorylation and 
markedly stimulates IRF4 transcriptional activity, and that Src mediates LMP1 activation of IRF4. 
As to more precise mechanism, we show that LMP1 physically interacts with c-Src, and the 
phosphatidylinositol 3 kinase (PI3K) subunit P85 mediates their interaction. Depletion of P85 by 
P85-specific short hairpin RNAs disrupts their interaction and diminishes IRF4 phosphorylation in 
EBV-transformed cells. Furthermore, we show that Src is upstream of PI3K for activation of both 
IRF4 and Akt. In turn, inhibition of PI3K kinase activity by the PI3K-speicfic inhibitor LY294002 
impairs Src activity. Our results show that LMP1 signaling is responsible for IRF4 activation, and 
further characterize the IRF4 regulatory network that is a promising therapeutic target for specific 
hematological malignancies.
INTRODUCTION
Epstein–Barr virus (EBV) latency programs are manifest as a large spectrum of lymphomas, 
and are associated with > 50% of AIDS-related lymphomas, including diffuse large B-cell 
lymphoma, post-transplant lymphoproliferative disease, Hodgkin’s lymphoma and non-
Hodgkin’s lymphoma.1–4 EBV is also the etiological pathogen of Burkitt’s lymphoma, 
Hodgkin’s lymphoma, nasopharyngeal carcinoma and infectious mononucleosis in 
immunocompetent individuals.3 EBV latent infection induces expression of interferon (IFN) 
regulatory factor 2 (IRF2), −4 and −7, three members with oncogenic properties in the IRF 
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family of transcription factors.5 However, their regulation and roles in EBV oncogenesis are 
largely unknown.6
The EBV principal oncoprotein latent membrane protein 1 (LMP1) is a pleiotropic factor 
that can cause cell transformation in vitro, as well as oncogenesis in transgenic mice.7 LMP1 
is a member of the tumor necrosis factor receptor superfamily, and is similar to with CD40 
and Toll-like receptors in signal transduction, including the activation of NFκB, mitogen-
activated protein kinases and phosphatidylinositol 3 kinase (PI3K)/Akt. It has been well 
documented that all of these downstream pathways contribute to LMP1 oncogenesis.8–11 
Along with others, we have shown compelling evidence that LMP1 also activates IRF7.12–14
The lymphocyte-specific factor IRF4 is overexpressed in EBV-infected cells,15–18 multiple 
myeloma,19,20 as well as in human T-cell leukemia virus-1-infected cell lines and associated 
adult T-cell leukemia.21–24 It is now understood that IRF4 is induced by LMP1,15,16,18 and 
stabilized by Epstein-Barr Virus Nuclear Antigen 3C,25 in EBV-infected cells. 
Overexpression of IRF4 is a hallmark of the Activated B-Cell like type of diffuse large B-
cell lymphoma and multiple myeloma.26,27 Genetic alterations of IRF4 have been found in 
MM, peripheral T-cell lymphomas28 and chronic lymphocytic leukemia.19,29 Recently, IRF4 
has been shown to be expressed in all LMP1-driven tumors in mice.30 In clinical practice, 
IRF4 is an important prognostic and diagnostic marker for different hematological 
malignancies.27,31–33 These lines of evidence strongly highlight the importance of IRF4 in 
hematological malignancies. However, the main body of these data has come from clinical 
observations. The lack of necessary molecular and mechanistic studies is a major barrier that 
prevents the development of therapeutic strategies to target the IRF4 network for treatment.
IRF4 is a quintessential ‘context-dependent’ factor that regulates unique targets in different 
contexts in cooperation with different co-regulators.32,34 We have identified B cell 
Integration Cluster (BIC), the gene encoding miR-155, as the first transcriptional target 
induced by IRF4 in virus-transformed cells.6 More recently, we have further identified IRF4-
associated unique molecular signatures in a panel of hematological malignancies.35 
Furthermore, we have recently demonstrated that IRF4 is activated through Src-mediated 
tyrosine phosphorylation in EBV-transformed cells.36 Correspondingly, Src is functional in 
these cells.36 These findings have prompted us to further identify the molecular mechanism 
underlying IRF4 activation in the context of EBV infection.
In this study, we aimed to identify the cellular signaling pathway responsible for IRF4 
activation by c-Src in the context of EBV infection. We show that LMP1 interacts with c-Src 
via P85 and triggers c-Src-mediated IRF4 tyrosine phosphorylation and transcriptional 
activity, and a positive regulatory circuit between P83 and c-Src is required for both 
downstream Akt and IRF4 activation.
RESULTS
LMP1 stimulates IRF4 tyrosine phosphorylation and transcriptional activity
We initially tested the ability of LMP1 to promote IRF4 phosphorylation. 293 cells were 
transfected with the constructs shown in Figure 1a, and the cell lysates were used for 
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immunoblotting with specific antibodies. c-Src was used as a positive control. As shown in 
Figure 1a, in the presence of LMP1, a specific band representing phosphorylated IRF4 was 
detected with the phospho-IRF4(Y121/124) antibody, indicating that LMP1 promotes IRF4 
tyrosine phosphorylation.
We then assayed the ability of LMP1 to potentiate IRF4-mediated transactivation. In 
addition to the wild-type LMP1, a panel of LMP1 point mutants were also used: LMP1-
PQAA, in which C-terminal activation region 1 (CTAR1) is disabled, LMP1-IID, in which 
(CTAR2) is disabled, and LMP1-IID/PQAA, in which both CTAR1 and -2 are disabled 
(Figure 1b). As shown in Figure 1c, LMP1 or IRF4 alone only slightly activate the 
Interferon-Stimulated Responsive Element (ISRE) promoter, but together they markedly 
activate it, up to 120-fold, when compared with the vector control. Mutation in either 
CTAR1 or CTAR2 or both significantly reduces the ability of LMP1 to transactivate IRF4. 
These results indicate that LMP1 potentiates IRF4-mediated transactivation, and both 
CTAR1 and -2 contribute.
We also used the IRF4 mutant, IRF4(Y121/124F) that is deficient in response to Src,36 to 
test its ability to respond to LMP1. As shown in Figure 1d, activation of IRF4(Y121/124F) 
by LMP1 is significantly impaired, compared with wild-type IRF4. As IRF4 (Y121/124) is 
still activated by LMP1, other sites on IRF4 may contribute to its activation by LMP1.
Collectively, these results indicate that LMP1 signaling can promote IRF4 phosphorylation 
and activation.
LMP1 interacts with c-Src in vitro and in vivo
As a tyrosine protein kinase, Src is normally maintained in an inactive form and is activated 
by autophosphorylation of Y418 or dephosphorylation of Y527.37 We have previously 
provided strong evidence that c-Src activates IRF4, and Src(Y418) is phosphorylated and 
therefore Src is active, in EBV-transformed cells.36 We have also shown that the total 
endogenous Src protein levels and activity correlate with the LMP1 protein levels in EBV 
latency.36 These observations suggest that, in EBV latency, LMP1 can stimulate Src 
activation, which then leads to IRF4 phosphorylation.
To further explore the possibility that Src is involved in LMP1 activation of IRF4, we tested 
if LMP1 physically interacts with Src. We transfected 293T cells with HA-LMP1 and Flag-
c-Src (or Flag-IRF4). Cell lysates were subjected to immunoprecipitation and then probed 
with HA antibody. As shown in Figure 2a, LMP1 clearly interacts with c-Src, but not with 
IRF4. We further demonstrated endogenous LMP1 and c-Src physically interact in EBV-
transformed cell lines, including IB4, SavIII and JiJoye via IP (Figure 2b). We conclude that 
LMP1 physically interacts with Src.
LMP1 has a SH3-binding region located in the N-terminal first 25 aa;38 whereas the Src 
kinase family contains an SH3 domain. We therefore then postulated that LMP1 interaction 
with Src is mediated by its SH3-binding region. To test this possibility, we performed IP 
with the use of LMP1Δ(12–20), an LMP1 deletion mutant in which the SH3-binding region 
is deleted (Figure 2c).38 Surprisingly, our results show that deletion of LMP1 SH3-binding 
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region did not affect its ability to bind to c-Src (Figure 2d). Correspondingly, LMP1Δ(12–
20) has a similar capability to the wild-type LMP1 in activating IRF4 transcription (Figure 
2e). These results show that the LMP1 SH3-binding region is responsible for neither Src 
binding nor IRF4 activation.
Taken together, LMP1 interacts with c-Src, but the N-terminal SH3-binding motif is neither 
responsible for their interaction, nor for IRF4 activation.
P85 mediates LMP1 and Src interaction
It has been shown that LMP1 CTAR1 directly interacts with P85, the regulatory subunit of 
PI3K,39 and c-Src binds to P85 through their SH3 domains.40 Thus, we speculated that P85 
mediates LMP1/Src interaction. To test this, we first confirmed the interaction between 
LMP1 and P85 in EBV-transformed cells (Figure 3a). Then, we determined whether LMP1 
CTAR1, the region responsible for P85 interaction,39 is also responsible for c-Src 
interaction. To this end, a panel of LMP1 deletion mutants, including CTAR1, CTAR2 and 
double deletion (DD), were used for IP to assess their abilities to interact with c-Src. As 
expected, LMP1 CTAR1 is also responsible for c-Src interaction (Figure 3b).
Furthermore, we show that endogenous Src and P85 interact in EBV-transformed cells 
(Figure 3c). More importantly, depletion of endogenous by short hairpin RNA (shRNA) in 
EBV-transformed cells disrupts the interaction between LMP1 and Src (Figure 3d). 
However, depletion of p110, the catalytic subunit of PI3K, had no detectable effect on 
LMP1/Src interaction (data not shown). These results indicate that P85 specifically mediates 
LMP1 interaction with and activation of Src.
Taken together, these results support our model that LMP1 CTAR1 recruits c-Src via P85.
PI3K and Src are required for LMP1 activation of IRF4
As LMP1 interacts with Src, we then assessed if Src activity is required for LMP1 activation 
of IRF4. To this end, we performed promoter–reporter assays with the use of the Src-specific 
inhibitor pyrazolo-[2,3-d]pyrimidine 2 (PP2), which we have shown to block Src(Y418) 
phosphorylation.36 Our results show that PP2 markedly decreases (up to 90%) IRF4 
transcriptional activity stimulated by LMP1 (Figure 4a), indicating that Src activity is 
required for IRF4 transcriptional activity stimulated by LMP1.
We further determined if PI3K activity is required for IRF4 activation. To this end, we first 
show that inhibition of PI3K activity by the PI3K-specific inhibitor LY294002 (designated 
as LY) significantly decreases IRF4 transcriptional activity stimulated by LMP1 (Figure 4a). 
Further, LY decreases IRF4 phosphorylation stimulated by LMP1 (Figure 4b), indicating 
that the PI3K pathway is required for IRF4 phosphorylation and functional activation. 
Autophosphorylation of Y418 or dephosphorylation of Y527 is required to switch Src from 
inactive to active form.37 Interestingly, the kinase CSK, which inactivates Src by 
phosphorylating Src (Y527), did not affect LMP1 activation of IRF4 in promoter–reporter 
assays (data not shown), implicating that Src(Y527) phosphorylation status is not involved 
in Src activation by LMP1.
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We further explored whether blockage of the LMP1/PI3K pathway affects IRF4 DNA-
binding activity. To this end, IB4 cells were treated with LY or PP2, and cells were then 
subjected to chromosome immunoprecipitation (ChIP). IRF4-DNA complexes were pulled 
down with an IRF4 antibody, and the recovered DNA fragments were subjected to real-time 
PCR amplification for a fragment containing ISRE of the BIC promoter.6 Results indicate 
that inhibition of PI3K or Src significantly reduces IRF4 DNA-binding activity (Figure 4c).
Together, our results indicate that both PI3K and Src downstream of LMP1 are involved in 
IRF4 activation.
A positive regulatory circuit between Src and PI3K for LMP1 activation of Akt and IRF4
There are reports showing that Src triggers PI3K activation in distinct biological 
contexts.40–42 A previous report has also shown that the levels of LMP1 and Src activity 
positively correlate in EBV latency, and a chimeric NGFP-LMP1 was able to activate the Src 
family member Fyn.43 As we show here that LMP1 interacts with c-Src via P85 (Figures 2 
and 3), we were interested in examining the possibility that c-Src mediates LMP1 activation 
of Akt. First, we show that transient expression of wild-type Flag-c-Src or the constitutively 
active mutant Flag-c-Src(Y527F), but not the kinase-dead mutant Flag-c-Src(Y418F), 
triggers Akt activation in DG75 B cells (Figure 5a). Further, we inhibited the Src activity in 
EBV-transformed cells using the Src-specific inhibitor PP2, and results show that Src 
inactivation markedly impairs Akt activity (Figure 5b). These results disclose that Src is 
upstream of P85 and promotes LMP1 activation of the PI3K/Akt pathway.
We also evaluated whether, in turn, PI3K has any effect on Src activation. To this end, we 
first blocked the kinase activity of PI3K by LY in EBV-transformed cells, and the results 
show that Src Y418 phosphorylation is remarkably reduced at the LY concentration of 80 
μM (Figure 5c). We further confirmed this finding using P85 shRNA, and results indicate 
that P85 has similar effect on Src activity (Figure 5d). Thus, PI3K and its kinase activity are 
involved in Src activation in the setting of EBV latent infection.
Together, these results (Figures 4 and 5) show that a positive regulatory circuit exists 
between Src and PI3K, and is required for the LMP1 signaling transduction to Akt and IRF4 
activation.
The level of IRF4 phosphorylation correlates with LMP1 and is dampened by the Src-
specific inhibitor PP2 in EBV+ cells
As the phospho-IRF4 (Y121/124) antibody we developed cannot detect endogenous IRF4 
phosphorylation in EBV latency by immunoblotting, we attempted to use an alternative 
method, flow cytometry, to address this issue. To this end, two pairs of cell lines, SavI and 
SavIII, and P3HR1 and JiJoye, were subjected to flow analysis using p-IRF4(Y121/124) and 
LMP1 antibodies. SavI and P3HR1, which express neither LMP1 nor IRF4, were used to 
normalize the basal levels. As shown in Figure 6a, we detected a considerably higher 
population of SavIII cells with phosphorylated IRF4 (21.7% compared with 0.049% in 
SavI), which positively correlate with their LMP1 expression levels. Similar results were 
obtained from P3HR1 and JiJoye cells (Figure 6a).
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We then treated these cells with the Src-specific inhibitor PP2, and assessed endogenous 
IRF4 phosphorylation by flow cytometry. As shown in Figure 6a, inhibition of Src with 15 
μM PP2 for 24 h results in marked decreases of endogenous IRF4 phosphorylation in these 
cells, with a 99% reduction observed in SavIII, and a 97% reduction in JiJoye cells. These 
results confirm that Src activity mediates LMP1 activation of IRF4.
We further evaluated IRF4 phosphorylation in SavIII cells after P85 depletion by shRNA. 
Our results show that p85 depletion results in significant reduction in p-IRF4-positive cell 
portion (Figure 6b). On the other hand, either LMP1 or Src promotes IRF4 phosphorylation 
when transiently expressed in EBV-negative BJAB cells (Figure 6c).
These results indicate that the levels of LMP1 and IRF4 phosphorylation positively correlate 
in EBV latency.
DISCUSSION
We have recently shown that IRF4 is activated through c-Src-mediated tyrosine 
phosphorylation, and is constitutively activated in EBV-transformed cells.36 In this study, we 
aimed to disclose the intracellular signaling pathway responsible for IRF4 activation in 
EBV-transformed cells. Our results definitively show that LMP1 promotes IRF4 tyrosine 
phosphorylation and markedly stimulates its transcriptional activity through recruiting Src 
via P85. Furthermore, we show a positive regulatory circuit between PI3K and P85 that is 
required for activation of both IRF4 and Akt downstream of LMP1 signaling. Our results 
support a model that LMP1 recruits Src via P85, resulting in Src autophosphorylation and 
activation, and then leads to IRF4 phosphorylation and activation (Figure 7).
It is notable that mutation in the TRAF-binding motif in LMP1 CTAR1 reduces the ability 
of LMP1 to activate IRF4 (Figure 1). This motif is well known to interact with TRAF1, -2, 
-3, -5 and -6. Previous reports have shown that TRAF2 and -6, together with P85, are in the 
signalosome for Akt activation by CD40 and OX40,44–46 which share signaling transduction 
mechanisms with LMP1. However, our preliminary results suggest that knockdown of either 
TRAF2 or -6 did not significantly impair the interaction between CTAR1 and P85; rather, 
these two ubiquitin E3 ligases may interact with IRF4 directly and enhance its 
transcriptional activity by promoting its K63-linked ubiquitination (data not shown). As both 
CTAR1 and -2 are known to interact with both TRAF2 and -6,47–49 the possible roles of 
TRAF2 and -6 in IRF4 ubiquitination and activation also account for our promoter–reporter 
results that both CTARs contribute to IRF4 transcriptional activity (Figure 1c). Further 
investigation is needed to make a definite conclusion whether any of these TRAFs mediates 
the interaction between LMP1 CTAR1 and P85 leading to downstream IRF4 and Akt 
activation, and to disclose K63-linked ubiquitination as a novel mechanism that cooperates 
with phosphorylation to activate IRF4.
In our earlier studies, we have provided solid evidence that LMP1 signaling activates 
another IRF family member, IRF7, and the underlying mechanism involves TRAF6- and 
RIP-mediated, K63-linked, regulatory ubiquitination.12–14 Although the Ser/Thr kinase 
responsible for LMP1 activation of IRF7 has not been identified, the PI3K axis is likely not 
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involved. Thus, LMP1 may use different but overlapping mechanisms to control activation 
of IRF7 and IRF4.
In addition to LMP1 signaling, other unidentified lymphocyte-specific pathways may also 
impact the outcomes of IRF4 transcriptional activation, considering the following facts: (i) 
IRF4 is also phosphorylated in other contexts, such as human T-cell leukemia virus-1-
infected cells, Hodgkin’s lymphoma cells50 and multiple myeloma cells,51 where LMP1 is 
absent; (ii) we have previously shown that, in addition to Src, other kinases including Alk 
and TNK also stimulate IRF4 transcriptional activity.36 Thus, IRF4 may be activated 
through different lymphocyte-specific signaling pathways that involve distinct kinases in 
different contexts; (iii) in the context of EBV latent infection, in addition to LMP1, LMP2A 
also activates the PI3K/Akt pathway in response to BCR signaling.52–55 It will be interesting 
to investigate if LMP2A stimulates IRF4 transcriptional activity through the Src/PI3K 
pathway axis; and (iv) the inhibitors LY294002 and PP2 are known to have cross-reactivity.
We have published a series of original findings related to this important project.32,35,36 The 
long-term efforts will characterize the IRF4-specific regulatory network that includes unique 
kinases involved in its activation in different contexts. From a clinical perspective, results 
from these studies will identify novel targets for potential therapeutic applications. For 
example, the Src inhibitors, Dasatinib, Sacracatinib and Bosutinib, which are used clinically, 
may have the potential to treat EBV-associated lymphomas by targeting the LMP1/IRF4 
pathway.
MATERIALS AND METHODS
Cell lines
SavI, SavIII, JiJoye, P3HR1, IB4 and LCL00045 are EBV-transformed B-cell lines. DG75 
and BJAB are EBV-negative human B-cell lines. All B-cell lines are cultured in RPMI1640 
medium plus 10% fetal bovine serum and antibiotics. 293 and 293T cells are cultured with 
Dulbecco’s modified Eagle’s medium plus 10% fetal bovine serum and antibiotics.
Plasmids, reagents and antibodies
IRF4 and LMP1 expression plasmids were described in our recent publication.36 Flag-
tagged LMP1 point mutants IID (384-YYD-386 mutated to 384-IID-386), PQAA (204-
PQQAT-208 mutated to 204-AQAAT-208) and IID/PQAA were generated by site-directed 
mutagenesis. 3XFlag-tagged LMP1 deletion mutants (LMP1 WT, LMP1(1–231), 
LMP1Δ(187–351) and LMP1(1–187)) were generated by mutagenesis and cloned in 
pCMV7.1/3XFlag. pSV2–LMP1 and its deletion mutant pSV2–LMP1Δ(12–20) were gifts 
from Dr Bill Sugden.38 P85-specific shRNA expression plasmids cloned in the vector TRIPz 
and control were purchased from Open Biosystems (Lafayette, CO, USA). pGL3/ISRE-Luc 
(IFN-stimulated response element-Luc) and Renilla (pRL-TK) were purchased from 
Stratagene (San Diego, CA, USA) and Promega (Fitchburg, WI, USA), respectively. 
Phospho-IRF4(Y121/124) was developed in rabbit and characterized in our recent 
publication.36 Mouse anti-Flag M2 (Sigma, St Louis, MO, USA), mouse anti-HA-7 (Roche, 
Indianapolis, IN, USA), mouse anti-LMP1 CS1-4 (Dako, Carpinteria, CA, USA), anti-IRF4 
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H140 (rabbit) and M17 (goat) (Santa Cruz, Dallas, TX, USA), anti-c-Src B12 (mouse) and 
N16 (rabbit) (Santa Cruz), rabbit anti-phospho-Src family (Y418) (Cell Signaling), Akt and 
p-Akt(S473) (Cell Signaling), and mouse anti-GAPDH (Santa Cruz) were used for 
immunoblotting and immunoprecipitation. Anti-mouse IgG APC and anti-rabbit IgG PE 
were purchased from eBioscience (San Diego, CA, USA). All second antibodies for 
immunoblotting were purchased from Cell Signaling. LY294002 and PP2 were purchased 
from Sigma and EMD Millipore (Billerica, MA, USA), respectively.
Promoter–reporter assay
293 cells in 24-well plates were transfected with 0.2 μg expression plasmids as indicated 
together with 40 ng ISRE-Luc and 10 ng Renilla as internal transfection control. Empty 
vector was used to equalize the total amounts of DNA in all transfections. Cells were 
collected 24 h after transfection. Luciferase activity was measured with equal amounts (10% 
of total for each sample) of protein lysates with the use of a Dual Luciferase Assay kit 
(Promega), on a Turner BioSystems Modulus II Microplate Multimode Reader (Promega).
Transfection
293 and 293T cells were transfected with Effectene reagent (Qiagen, Valencia, CA, USA), 
and B cells were transfected with Lonza (Walkersville, MD, USA) Human B cell 
Nucleofector Kits following the manufacturer’s instructions. P85 shRNA in TRIPz were 
introduced into cells by retrovirus-mediated transfection. Retrovirus packing, production and 
infection were detailed in our previous publication.6 Stable transfectants were selected with 
1 μg/ml puromycin for 2 weeks. Expression of TRIPz/shRNA is induced by 1 μg/ml 
doxycycline (Sigma).
Flow cytometry
Cell pellets were washed with phosphate-buffered saline and fixed in fixation buffer 
(Biolegend, San Diego, CA, USA), permeabilized with permeabilization solution 
(eBioscience), and then incubated with mouse LMP1 CS1-4 and rabbit p-IRF4(Y121/124) 
antibodies for 40 min. After washing with flow cytometry buffer, cells were incubated 
further with anti-mouse IgG APC and anti-rabbit IgG PE for 25 min, and then followed by 
flow cytometry analysis with a Flow Cytometer (Accuri, BD Biosciences, Franklin Lakes, 
NJ, USA) and BD Accuri C6 Software (BD Biosciences, San Jose, CA, USA). Data were 
further analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA). The 
fluorescence minus one strategy was used to determine background level and to adjust 
multicolor compensation for cell gating.
In vitro immunoprecipitation
293T cells in 60-mm dishes were transfected with 1 μg each indicated expression plasmids. 
Cells were harvested 48 h after transfection, and lysed in 1 ml NP-40 lysis buffer (10 mM 
Tris, pH7.5, 0.5% NP-40, 0.5% TritonX-100, 2.5 mM KCl, 150 mM NaCl, 30 mM β-
glycerophosphate, 50 mM NaF, 1 mM NaOV4, and cocktail protease inhibitors (Sigma)). 
Supernatants were incubated with indicated antibodies. Protein A/G beads (Santa Cruz) 
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were then added and incubated for 1 h and then subjected to extensive washes with NP-40 
lysis buffer. Immunoblotting was performed with antibodies indicated.
In vivo immunoprecipitation
EBV-transformed cells (5 × 106 for each) were lysed in NP-40 lysis buffer. Supernatants 
were collected and pre-cleared with normal serum (2 μl for 1 ml lysates containing about 1 
mg total proteins). The lysates were then incubated overnight with 2 μg rabbit Src antibody 
N16 or LMP1 antibody CS1-4 or normal serum (21st Century Biochemicals Inc., 
Marlborough, MA, USA). In all, 50 μl protein A/G beads (Santa Cruz) were then added and 
incubated for 30 more minutes. Beads were extensively washed with NP-40 lysis buffer and 
subjected to immunoblotting analysis.
Immunoblotting
Proteins were separated by 10% Acr:bis gel, and then transferred to nitrocellulose 
membranes followed by immunoblotting with corresponding antibodies. Signals were 
detected with an enhanced chemiluminescence kit following the manufacturer’s protocol 
(Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Chromosome immunoprecipitation
ChIP was performed with the use of ChIP-IT Express Enzymatic kit (Active Motif, 
Carlsbad, CA, USA). Briefly, IB4 cells were treated with LY or PP2, and harvested after 24 
h. Cells were subjected to crosslinking by adding formaldehyde to a final concentration of 
1% for 30 min at room temperature with slow rotation. Crosslinking was stopped by adding 
glycine to a final concentration of 125 mM for 5 min. Shearing and enzymatic digestion of 
chromatin, IP with IRF4 antibody M17, and DNA recovery were performed following the 
manufacturers’ instructions. Quantitative PCR was performed with the human BIC promoter 
ISRE primers: 5′-CCCCTCCAGCCGACTG-3′ (forward) and 5′-AACACACGCCGT 
GTAC-3′ (reverse), and β-actin promoter primers (control): 5′-CCAAC 
AAAGCACTGTGG-3′ (forward) and 5′-GGGCGAAGGCAACGC-3′ (reverse).6
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Figure 1. 
LMP1 promotes IRF4 transcriptional activity and phosphorylation. (a) LMP1 stimulates 
IRF4 phosphorylation. 293 cells in 60-mm dishes were transfected with 1 μg LMP1 (or 
Flag-c-Src) and 1 μg IRF4 expression plasmids. Cells were collected 48 h post-transfection 
and analyzed for IRF4 phosphorylation with p-IRF4(Y121/124). (b) A diagram showing the 
LMP1 point mutants. (c) and (d) LMP1 promotes IRF4 transcriptional activity. 293 cells in 
24-well plates were transfected with 50 ng IRF4 or the mutant IRF4(Y121/124 F) and 50 ng 
LMP1 or its mutants expression plasmids, 40 ng pGL3/Interferon-Stimulated Responsive 
Element (ISRE)-Luc and 10 ng Renilla. Dual luciferase assay was performed. Results are 
the averages ± s.e. of duplicates. Representative results from at least three independent 
experiments are shown. The ability of the vector control to activate the promoter construct 
was set to 1.
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Figure 2. 
LMP1 interacts with Src. (a) LMP1 interacts with Src in vitro. 293T cells in 60-mm dishes 
were transfected with 1 μg HA-LMP1 (or Flag-c-Src) and 1 μg Flag-IRF4 expression 
plasmids. Cells were collected 48 h post-transfection and then subjected to 
immunoprecipitation with the Flag antibody clone M2. Beads were washed extensively and 
then subjected to immunoblotting with the HA antibody clone HA-7. Inputs (5%) were 
subjected to immunoblotting with the indicated antibodies. (b) Endogenous LMP1 and Src 
interact in EBV latency. Cell lysates (approximately 1 mg of total proteins in each sample) 
prepared from JiJoye, IB4 and SavIII cells were subjected to immunoprecipitation with the 
c-Src antibody clone N16 (or rabbit serum as control). Beads were washed extensively and 
probed with LMP1 and Src antibodies. Inputs (5%) were also probed with these antibodies. 
(c) A diagram showing the LMP1 deletion mutant LMP1Δ(12–20). (d) The LMP1 SH3-
binding region is not required for Src interaction. 293T cells in 60-mm dishes were 
transfected with 1 μg LMP1 or LMP1Δ(12–20) and 1 μg Flag-c-Src expression plasmids. 
Cells were collected 48 h post-transfection and then subjected to immunoprecipitation with 
the LMP1 antibody clone CS1-4. Beads were washed extensively and then subjected to 
immunoblotting with the Flag antibody clone M2 and the LMP1 antibody. Inputs (5% of 
total lysates) were subjected to immunoblotting with indicated antibodies. (e) The LMP1 
SH3-binding region is not required for IRF4 activation. The 293 cells in 24-well plates were 
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transfected with 50 ng IRF4 and 50 ng LMP1 (or LMP1Δ(12–20)) expression plasmids, 40 
ng pGL3/IFNβ-Luc and 10 ng Renilla. Dual luciferase assay was performed. Results are the 
averages ± s.e. of duplicates. Representative results from at least three independent 
experiments are shown. The ability of the vector control to activate the promoter construct 
was set to 1.
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Figure 3. 
P85 mediates LMP1 and Src interaction. (a) Cell lysates (approximately 1 mg of total 
proteins in each sample) prepared from JiJoye and IB4 cells were subjected to 
immunoprecipitation with the LMP1 antibody clone CS1-4 (or mouse serum as control). 
Beads were washed extensively and probed with P85 and LMP1 antibodies. Inputs (5%) 
were also probed with these antibodies. (b) LMP1 CTAR1 is responsible for its interaction 
with Src. 293T cells in 60-mm dishes were transfected with 1 μg 3XMyc-Src and 1 μg Flag-
LMP1 or its deletion mutants as indicated. Cells were collected 48 h post-transfection and 
then subjected to immunoprecipitation with 1.5 μg Myc antibody 9E10 (Roche). Beads were 
washed extensively and then subjected to immunoblotting with the Flag antibody clone M2 
and Myc antibody 9E10. Loading control is Ponceau S staining. Upper panel shows a 
diagram showing the LMP1 protein structure. (c) Endogenous P85 and Src interact in EBV 
latency. Cell lysates (approximately 1 mg of total proteins in each sample) prepared from 
JiJoye, IB4 and SavIII cells were subjected to immunoprecipitation with the c-Src antibody 
clone N16 (or rabbit serum as control). Beads were washed extensively and probed with P85 
and Src antibodies. (d) P85 depletion disrupts the interaction between LMP1 and Src. IB4 
cells were infected with retrovirus expressing P85-specific shRNAs (or control). Stable 
transfectants were selected with 1 μg/ml puromycin for 2 weeks. shRNA expression was 
induced by 1 μg/ml doxycycline for 3 days. Knockdown efficiency is shown in the lower 
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panel. Cells were then harvested and subjected to IP with the Src antibody clone N16, and 
then probed with the LMP1 antibody clone CS1-4. Representative results from at least three 
independent experiments are shown.
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Figure 4. 
PI3K and Src are required for LMP1 activation of IRF4. (a) The PI3K-specific inhibitor 
LY294002, and the Src-specific inhibitor PP2, inhibit LMP1 activation of IRF4. 293 cells in 
24-well plates were transfected with 50 ng IRF4 and 50 ng LMP1 expression plasmids, 40 
ng pGL3/ISRE-Luc and 10 ng Renilla. Five hours later, cells were treated with the following 
inhibitors for 20 h: 20 μM LY or 40 μM PP2 (or DMSO as control). Dual luciferase assay 
was performed. Results are the averages ± s.e. of duplicates. Representative results from at 
least five independent experiments are shown. The ability of the vector control to activate the 
promoter construct in each treatment group was set to 1. (b) Inhibition of LMP1-promoted 
IRF4 phosphorylation by LY and PP2. 293T cells in six-well plates were transfected with 
0.2 μg Flag-LMP1 and 0.2 μg Flag-IRF4 expression plasmids. Cells were then treated with 
20 μM LY or 40 μM PP2 (or DMSO as control) for 20 h before harvest for immunoblotting 
with the indicated antibodies. (c) IB4 cells (2 × 106 for each treatment) were treated with 20 
μM LY or 20 μM PP2 for 24 h. Cells were then subjected to ChIP assay. For each sample, 
DNA pellets were dissolved in 200 μl ddH2O, and 15 μl was used for quantitative PCR using 
the B cell Integration Cluster (BIC) and β-actin promoter primers. Representative results 
from at least three independent experiments are shown.
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Figure 5. 
A positive circuit between Src and PI3K for LMP1 activation of Akt and IRF4. (a) Src 
triggers Akt phosphorylation and activation. DG75 cells (1 × 106) were transfected with 
Flag-Src or its mutants Flag-Src(Y527F) or Flag-Src(Y418F), or vector control. Cells were 
subjected to serum-free treatment for 24 h. Cells were then harvest for immunoblotting with 
the indicated antibodies. (b) Inhibition of Src activity abolishes Akt activity in EBV-
transformed cells. JiJoye, IB4 and LCL00045 cells were treated with 20 μM Src-specific 
inhibitor PP2 for 24 h in serum-free medium before subjected to immunoblotting analysis. 
(c) LY inhibits endogenous Src Y418 phosphorylation. JiJoye, IB4 and SavIII were treated 
with 10 μM 20 or 80 μM LY (or DMSO control) for 48 h. Cell lysates were then prepared 
and probed with the indicated antibodies. (d) P85 depletion diminishes Src phosphorylation 
and activity. IB4 cells were infected with retrovirus expressing P85-specific shRNAs (or 
control). Stable transfectants were selected with 1 μg/ml puromycin for 2 weeks. shRNA 
expression was induced by 1 μg/ml doxycycline for 3 days. Cells were then harvested and 
subjected to immunoblotting with the indicated antibodies. Representative results from at 
least three independent experiments are shown.
Wang et al. Page 19
Oncogene. Author manuscript; available in PMC 2017 November 14.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 6. 
The level of IRF4 phosphorylation correlates with LMP1 and is dampened by the Src-
specific inhibitor PP2 in EBV+ cells. (a) Cells were collected, washed and fixed after 
treatment with 15 μM PP2 or DMSO (control) for 24 h. Cells were then permeabilized, and 
incubated with mouse anti-LMP1 antibody (Dako) and rabbit anti-p-IRF4 antibody (21st 
Century Biochemicals). After wash, cells were incubated with anti-mouse IgG APC 
(eBioscience) and anti-rabbit PE (eBioscience) before subjected to flow cytometry analysis. 
Q4 represents the portion of LMP1+/p-IRF4+ cells. (b) SavIII cells were transfected with 
p85 shRNA (#1) (or control). shRNA expression was induced by 1 μg/ml doxycycline for 3 
days. p-IRF4 was then evaluated by flow. P = 0.0007 (unpaired t-test). (c) BJAB cells were 
transfected with IRF4, IRF4 plus LMP1 (or c-Src as a positive control). Cells were subjected 
to flow analysis after 48 h. Statistical analysis was performed for three independent flow 
analyses. Results are the averages ± s.d. Representative results from at least three 
independent experiments are shown.
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Figure 7. 
A diagram showing LMP1 signaling transduction to IRF4 activation. LMP1 is known to 
induce IRF4 expression via NFκB. In our current study, we show that LMP1 recruits Src 
through P85 that is a subunit of the PI3K kinase complex, and that these two kinases 
constitutes a positive regulatory circuits, leading to Akt and IRF4 activation. Activated IRF4, 
in cooperation with a co-factor, regulates expression of its targets, such as IFI27, IFI44, 
CFLAR35 and BIC/miR-155.6
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